Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Yi Wang, Wei LIU, Huimin Liu, Qi Wang, Weiwei Sui, Rui Lv, Lugui Qiu, Dehui Zou
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417018402
Cites:
Cited by:
Related to: